Habib George, Avisar Irit
Rheumatology Unit, Laniado Hospital and Rheumatology Clinic, Nazareth Hospital and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Cann Pharmaceutical, Israel.
Pain Res Treat. 2018 Jul 22;2018:7829427. doi: 10.1155/2018/7829427. eCollection 2018.
To report on the habits of cannabis consumption among fibromyalgia patients in Israel.
An Internet-based questionnaire was posted to three large fibromyalgia Facebook groups in our country. The questionnaire was anonymous and included demographic, clinical, and cannabis-related questions, including acquisition of a license for medical cannabis (MC) method and amount of cannabis consumption; need to buy cannabis beyond the medical allowance; effect of cannabis on pain, sleep, depression, and anxiety; adverse effects of cannabis; feelings of dependence on cannabis or other meds; the involvement of family members; tendency to drive after using cannabis; and employment and social disability status.
Of 2,705 people, 383 (14%) responded to the questionnaire, with a mean age of 42.2±14.2 years. Of the responders, 84% reported consuming cannabis, and 44% were licensed for MC. The mean amount per month of cannabis consumed was 31.4±16.3g, and 80% of cannabis consumers (CC) smoked pure cannabis or cannabis mixed with tobacco. Pain relief was reported by 94% of CC, while 93% reported improved sleep quality, 87% reported improvement in depression, and 62% reported improvement in anxiety. Of MC-licensed CC, 55% bought cannabis beyond the medical allowance on the black market. Adverse effects were reported by 12% of CC. Only 8% reported dependence on cannabis. Most CC (64%) worked either full- or part-time jobs, and 74% reported driving "as usual" under cannabis use.
Cannabis consumption among fibromyalgia patients in our country is very common and is mostly not licensed. Nearly all CC reported favorable effects on pain and sleep, and few reported adverse effects or feeling of dependence on cannabis.
报告以色列纤维肌痛患者的大麻消费习惯。
在我国的三个大型纤维肌痛脸书群组中发布了一份基于网络的调查问卷。该问卷为匿名问卷，包括人口统计学、临床和与大麻相关的问题，包括医用大麻（MC）许可证的获取、大麻消费方式和消费量；超出医疗许可购买大麻的需求；大麻对疼痛、睡眠、抑郁和焦虑的影响；大麻的不良反应；对大麻或其他药物的依赖感；家庭成员的参与情况；使用大麻后驾车的倾向；以及就业和社会残疾状况。
在2705人中，383人（14%）回复了问卷，平均年龄为42.2±14.2岁。在回复者中，84%报告消费过大麻，44%持有MC许可证。每月大麻的平均消费量为31.4±16.3克，80%的大麻消费者（CC）吸食纯大麻或大麻与烟草混合的产品。94%的CC报告疼痛得到缓解，93%报告睡眠质量改善，87%报告抑郁有所改善，62%报告焦虑有所改善。在持有MC许可证的CC中，55%在黑市上超出医疗许可购买大麻。12%的CC报告有不良反应。只有8%报告对大麻有依赖。大多数CC（64%）从事全职或兼职工作，且74%报告在使用大麻的情况下“照常”开车。
我国纤维肌痛患者中大麻消费非常普遍，且大多没有许可证。几乎所有CC都报告大麻对疼痛和睡眠有积极影响，很少有人报告有不良反应或对大麻有依赖感。
